Justice through the J88: The doctor's role in the criminal justice system by Rowe, K, Botha, H, Mahomed, H, Schlemmer, A

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial by Tameris, MD, Hatherill, M, Landry, B, Scriba, T, Snowden, M, Lockhart, S, Lockhart, S, Shea, J, McClain, J, Hussey, G, Hussey, G, Hanekom, W, Mahomed, H, Mahomed, H, McShane, H

Publishing vaccine trial results – Does there have to be a delay? by McShane, H, Tameris, D, Landry, B, Snowden, M, Lockhart, S, Scriba, T, Mahomed, H, Hatherill, M

Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function. by Dintwe, O, Day, C, Smit, E, Nemes, E, Gray, C, Tameris, M, Mcshane, H, Mahomed, H, Hanekom, W, Scriba, T

The role of clinical symptoms in the diagnosis of intrathoracic tuberculosis in young children by Mcshane, H, Tameris, M, Luabeya, K, Geldenhuys, H, Scriba, T, Hussey, G, Mahomed, H, Landry, B, Hanekom, W, Hatherill, M

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. by Tameris, M, Geldenhuys, H, Luabeya, A, Smit, E, Hughes, J, Vermaak, S, Hanekom, W, Hatherill, M, Mahomed, H, Mcshane, H, Scriba, T

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses by Tameris, M, Geldenhuys, H, Luabeya, A, Smit, E, Hughes, J, Vermaak, S, Hanekom, W, Hatherill, M, Mahomed, H, McShane, H, Scriba, T

Comparison of haematology and biochemistry parameters in healthy South African infants with laboratory reference intervals. by Schmidt, B, Tameris, M, Geldenhuys, H, Luabeya, A, Bunyasi, E, Hawkridge, T, McClain, J, Mahomed, H, Scriba, T, McShane, H, Hatherill, M

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. by Tameris, MD, Hatherill, M, Landry, B, Scriba, T, Snowden, M, Lockhart, S, Shea, J, McClain, J, Hussey, G, Hanekom, W, Mahomed, H, McShane, H

Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination by Bunyasi, E, Luabeya, A, Tameris, M, Geldenhuys, H, Mulenga, H, Landry, B, Scriba, T, Schmidt, B, Hanekom, W, Mahomed, H, McShane, H, Hatherill, M

Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study by Andrews, J, Nemes, E, Tameris, M, Landry, B, Mahomed, H, McClain, J, Fletcher, H, Hanekom, W, Wood, R, McShane, H, Scriba, T, Hatherill, M

Risk of disease after isoniazid preventive therapy for mycobacterium tuberculosis exposure in young HIV uninfected children by Mcshane, H, Tameris, M, Luabeya, K, Geldenhuys, H, Scriba, T, Hussey, G, Mahomed, H, Landry, B, Hanekom, W, Hatherill, M, Toefey, A, Hughes, E, Van Schalkwyk, A

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response. by Matsumiya, M, Harris, SA, Satti, I, Stockdale, L, Tanner, R, O'Shea, M, Tameris, M, Mahomed, H, Hatherill, M, Scriba, T, Hanekom, W, Mcshane, H, Fletcher, H

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response by Matsumiya, M, Harris, SA, Satti, I, Stockdale, L, Tanner, R, O'Shea, M, Tameris, M, Mahomed, H, Hatherill, M, Scriba, T, Hanekom, W, McShane, H, Fletcher, H

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. by Hawkridge, T, Scriba, T, Gelderbloem, S, Smit, E, Tameris, M, Moyo, S, Lang, T, Veldsman, A, Hatherill, M, Merwe, L, Fletcher, H, Mahomed, H, Hill, A, Hanekom, W, Hussey, G, Mcshane, H

Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents by Rustomjee, R, McClain, B, Brennan, M, McLeod, R, Chetty-Makkan, C, Mcshane, H, Hanekom, W, Steel, G, Mahomed, H, Ginsberg, A, Shea, J, Lockhart, S, Self, S, Churchyard, G

Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents. by Rustomjee, R, McClain, B, Brennan, M, McLeod, R, Chetty-Makkan, C, McShane, H, Hanekom, W, Steel, G, Mahomed, H, Ginsberg, A, Shea, J, Lockhart, S, Self, S, Churchyard, G

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A by Harris, SA, Satti, I, Matsumiya, M, Stockdale, L, Chomka, A, Tanner, R, O'Shea, MK, Thomas, Z-R, Tameris, M, Mahomed, H, Scriba, TJ, Hanekom, WA, Fletcher, HA, McShane, H

Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. by Tameris, M, McShane, H, McClain, J, Landry, B, Lockhart, S, Luabeya, A, Geldenhuys, H, Shea, J, Hussey, G, van der Merwe, L, de Kock, M, Scriba, T, Walker, R, Hanekom, W, Hatherill, M, Mahomed, H

Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG by Tameris, M, McShane, H, McClain, J, Landry, B, Lockhart, S, Luabeya, A, Geldenhuys, H, Shea, J, Hussey, G, Van Der Merwe, L, De Kock, M, Scriba, T, Walker, R, Hanekom, W, Hatherill, M, Mahomed, H